# Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

> **NCT05975840** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 518 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** FLU Q-PAN H5N8 375_B
- **BIOLOGICAL:** FLU Q-PAN H5N8 375_A
- **BIOLOGICAL:** FLU Q-PAN H5N8 750_B
- **BIOLOGICAL:** FLU Q-PAN H5N8 750_A

## Key facts

- **NCT ID:** NCT05975840
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-03
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-09-19
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975840, "Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05975840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*